New hope for stubborn nerve disorder? drug combo tested in 76 patients
NCT ID NCT07597733
First seen May 20, 2026 · Last updated May 23, 2026 · Updated 1 time
Summary
This study tests whether adding telitacicept to standard treatment helps people with refractory chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. About 76 adults aged 18-65 will receive either standard care alone or standard care plus telitacicept for 24 weeks. Researchers will measure improvements in disability, muscle strength, and walking ability, and track side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
Conditions
Explore the condition pages connected to this study.